Meet the 5%-Yielding Dividend Stock That Could Soar in 2026

Kenvue (KVUE), the consumer health spin-off from Johnson & Johnson, has seen its shares decline over 20% this year, pushing its dividend yield above 5%, primarily due to flat sales, falling earnings, and concerns linking Tylenol to autism. Following pressure from activist investor Starboard Value, the company has refreshed its board and appointed new senior leadership, who are now exploring strategic alternatives, including optimizing its brand portfolio, enhancing operational performance, and potentially divesting its skin health business, valued between $6 billion and $9 billion. These strategic initiatives, coupled with any positive developments regarding Tylenol litigation, are anticipated to drive a significant recovery and unlock shareholder value by 2026, positioning Kenvue as a potential turnaround play.

Analysis

Kenvue (KVUE) has experienced a significant share price decline exceeding 20% year-to-date, pushing its dividend yield above 5%. This underperformance stems from fundamental challenges, including flat sales last year and a 4% decline in Q2 2025 sales, coupled with tumbling earnings due to higher costs, and legal concerns linking Tylenol to autism. Despite reporting nearly $15.5 billion in sales and over $1 billion in profit last year, these issues highlight operational and reputational pressures on the recently independent consumer health company.

Activist investor Starboard Value has successfully driven substantial governance changes at Kenvue, leading to a refreshed board and the appointment of a new senior leadership team, including a new CFO and interim CEO. This leadership overhaul signals a strong commitment to addressing the company's underperformance and unlocking shareholder value.

The new management is actively exploring strategic alternatives, such as optimizing the brand portfolio, enhancing operational performance, and potentially divesting non-core assets. Analysts estimate the skin health business, a potential divestiture target, could be valued between $6 billion and $9 billion, providing significant capital to bolster the balance sheet or fund acquisitions. These strategic initiatives, alongside any positive developments regarding the Tylenol litigation, are anticipated to drive a recovery and position Kenvue as a turnaround candidate by 2026.

Key Decisions for Investors

• Monitor the progress of Kenvue's strategic review, particularly any announcements regarding asset divestitures like the skin health business, as these could significantly impact valuation and capital allocation.
• Assess the effectiveness of the new management team's initiatives in driving sales growth and improving profit margins, given the recent flat to declining sales and cost pressures.
• Keep a close watch on developments concerning the Tylenol litigation, as positive news could substantially de-risk the investment and serve as a major upside catalyst for the stock.
• Consider Kenvue as a potential turnaround play, balancing the current operational challenges and legal risks against the attractive dividend yield and the potential for strategic value creation from ongoing restructuring efforts.